Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

A precision medicine approach to repetitive Transcranial Magnetic Stimulation (rTMS).

Leuchter AF, Corlier J.

Brain Stimul. 2018 May - Jun;11(3):463-464. doi: 10.1016/j.brs.2018.02.003. Epub 2018 Feb 16. No abstract available.

PMID:
29501433
2.

Change in Quantitative EEG Theta Cordance as a Potential Predictor of Repetitive Transcranial Magnetic Stimulation Clinical Outcome in Major Depressive Disorder.

Hunter AM, Nghiem TX, Cook IA, Krantz DE, Minzenberg MJ, Leuchter AF.

Clin EEG Neurosci. 2018 Sep;49(5):306-315. doi: 10.1177/1550059417746212. Epub 2017 Dec 10.

PMID:
29224411
4.

Evaluating cognitive complaints in breast cancer survivors with the FACT-Cog and quantitative electroencephalography.

Van Dyk K, Hunter AM, Ercoli L, Petersen L, Leuchter AF, Ganz PA.

Breast Cancer Res Treat. 2017 Nov;166(1):157-166. doi: 10.1007/s10549-017-4390-6. Epub 2017 Jul 13.

PMID:
28707203
5.

Defining Treatment-Resistant Depression.

Fogelson DL, Leuchter A.

JAMA Psychiatry. 2017 Jul 1;74(7):758-759. doi: 10.1001/jamapsychiatry.2017.0967. No abstract available.

PMID:
28564677
6.

Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?

Leuchter MK, Donzis EJ, Cepeda C, Hunter AM, Estrada-Sánchez AM, Cook IA, Levine MS, Leuchter AF.

Front Neurol. 2017 Mar 30;8:91. doi: 10.3389/fneur.2017.00091. eCollection 2017. Review.

7.

Can neurophysiologic measures serve as biomarkers for the efficacy of repetitive transcranial magnetic stimulation treatment of major depressive disorder?

Kobayashi B, Cook IA, Hunter AM, Minzenberg MJ, Krantz DE, Leuchter AF.

Int Rev Psychiatry. 2017 Apr;29(2):98-114. doi: 10.1080/09540261.2017.1297697. Epub 2017 Mar 31. Review.

PMID:
28362541
8.

Escitalopram but not placebo modulates brain rhythmic oscillatory activity in the first week of treatment of Major Depressive Disorder.

Leuchter AF, Hunter AM, Jain FA, Tartter M, Crump C, Cook IA.

J Psychiatr Res. 2017 Jan;84:174-183. doi: 10.1016/j.jpsychires.2016.10.002. Epub 2016 Oct 7.

PMID:
27770740
9.

Neurophysiologic Correlates of Headache Pain in Subjects With Major Depressive Disorder.

Scanlon GC, Jain FA, Hunter AM, Cook IA, Leuchter AF.

Clin EEG Neurosci. 2017 May;48(3):159-167. doi: 10.1177/1550059416632411. Epub 2016 Mar 21.

PMID:
27000108
10.

Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future.

Koek RJ, Schwartz HN, Scully S, Langevin JP, Spangler S, Korotinsky A, Jou K, Leuchter A.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Oct 3;70:170-218. doi: 10.1016/j.pnpbp.2016.01.015. Epub 2016 Feb 6. Review.

PMID:
26854815
11.

Trigeminal Nerve Stimulation for Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder.

Cook IA, Abrams M, Leuchter AF.

Neuromodulation. 2016 Apr;19(3):299-305. doi: 10.1111/ner.12399. Epub 2016 Jan 28.

PMID:
26818103
12.

Authors' reply.

Leuchter AF, Hunter AM, Tartter M, Cook IA.

Br J Psychiatry. 2015 Dec;207(6):561-2. doi: 10.1192/bjp.207.6.561b. No abstract available.

PMID:
26628700
13.

Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder.

Hunter AM, Cook IA, Tartter M, Sharma SK, Disse GD, Leuchter AF.

Psychopharmacology (Berl). 2015 Oct;232(20):3833-40. doi: 10.1007/s00213-015-4047-2. Epub 2015 Aug 29.

PMID:
26319158
14.

Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression.

Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O'Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS.

Brain Stimul. 2015 Jul-Aug;8(4):787-94. doi: 10.1016/j.brs.2015.05.005. Epub 2015 May 22.

PMID:
26143022
15.

Author's reply: To PMID 25213159.

Leuchter AF, Hunter AM, Tartter M, Cook IA.

Br J Psychiatry. 2015 May;206(5):435. doi: 10.1192/bjp.206.5.435. No abstract available.

PMID:
25934309
16.

A role for profiles of patient-specific depression characteristics and socioeconomic factors in the prediction of antidepressant treatment outcome.

Jain FA, Hunter AM, Leuchter AF, Brooks JO 3rd.

J Clin Psychiatry. 2015 Mar;76(3):327. doi: 10.4088/JCP.14lr09483. No abstract available.

17.

Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments.

Leuchter AF, Hunter AM, Krantz DE, Cook IA.

Ann N Y Acad Sci. 2015 May;1344:78-91. doi: 10.1111/nyas.12742. Epub 2015 Mar 23. Review.

18.

Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder.

Leuchter AF, Hunter AM, Krantz DE, Cook IA.

Dialogues Clin Neurosci. 2014 Dec;16(4):525-37. Review.

19.

An eight-week, open-trial, pilot feasibility study of trigeminal nerve stimulation in youth with attention-deficit/hyperactivity disorder.

McGough JJ, Loo SK, Sturm A, Cowen J, Leuchter AF, Cook IA.

Brain Stimul. 2015 Mar-Apr;8(2):299-304. doi: 10.1016/j.brs.2014.11.013. Epub 2014 Nov 28.

PMID:
25533244
20.

The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder.

Caudill MM, Hunter AM, Cook IA, Leuchter AF.

Clin EEG Neurosci. 2015 Oct;46(4):277-84. doi: 10.1177/1550059414532443. Epub 2014 Sep 24.

Supplemental Content

Loading ...
Support Center